The stock price of Niagen Bioscience Inc (NASDAQ: NAGE) has surged by 9.35 when compared to previous closing price of 8.45, but the company has seen a 22.22% gain in its stock price over the last five trading sessions. zacks.com reported 2025-05-07 that Niagen Bioscience (NAGE) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.01 per share a year ago.
Is It Worth Investing in Niagen Bioscience Inc (NASDAQ: NAGE) Right Now?
Niagen Bioscience Inc (NASDAQ: NAGE) has a higher price-to-earnings ratio of 53.50x compared to its average ratio. NAGE has 36-month beta value of 1.99. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NAGE is 49.16M, and currently, short sellers hold a 4.33% ratio of that float. The average trading volume of NAGE on May 09, 2025 was 994.22K shares.
NAGE’s Market Performance
The stock of Niagen Bioscience Inc (NAGE) has seen a 22.22% increase in the past week, with a 70.48% rise in the past month, and a 62.39% gain in the past quarter. The volatility ratio for the week is 7.68%, and the volatility levels for the past 30 days are at 6.08% for NAGE. The simple moving average for the last 20 days is 26.16% for NAGE stock, with a simple moving average of 71.41% for the last 200 days.
Analysts’ Opinion of NAGE
B. Riley Securities, on the other hand, stated in their research note that they expect to see NAGE reach a price target of $2.40, previously predicting the price at $6. The rating they have provided for NAGE stocks is “Neutral” according to the report published on August 11th, 2022.
ROTH Capital gave a rating of “Buy” to NAGE, setting the target price at $7 in the report published on March 08th of the previous year.
NAGE Trading at 28.97% from the 50-Day Moving Average
After a stumble in the market that brought NAGE to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.65% of gains for the given period.
Volatility was left at 6.08%, however, over the last 30 days, the volatility rate increased by 7.68%, as shares surge +52.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +63.25% upper at present.
During the last 5 trading sessions, NAGE rose by +22.22%, which changed the moving average for the period of 200-days by +211.11% in comparison to the 20-day moving average, which settled at $7.32. In addition, Niagen Bioscience Inc saw 74.18% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NAGE starting from Lopez Carlos Luis, who purchase 273 shares at the price of $7.86 back on Mar 07 ’25. After this action, Lopez Carlos Luis now owns 2,251 shares of Niagen Bioscience Inc, valued at $2,146 using the latest closing price.
Jaksch Frank L Jr, the Director of Niagen Bioscience Inc, sale 37,161 shares at $6.19 during a trade that took place back on Dec 13 ’24, which means that Jaksch Frank L Jr is holding 244,179 shares at $229,956 based on the most recent closing price.
Stock Fundamentals for NAGE
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.62 for the gross margin
The net margin for Niagen Bioscience Inc stands at 0.09. The total capital return value is set at 0.15. Equity return is now at value 33.47, with 20.83 for asset returns.
Based on Niagen Bioscience Inc (NAGE), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at 4.57.
Currently, EBITDA for the company is 9.21 million with net debt to EBITDA at -4.54. When we switch over and look at the enterprise to sales, we see a ratio of 6.79. The receivables turnover for the company is 12.82for trailing twelve months and the total asset turnover is 1.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.66.
Conclusion
To put it simply, Niagen Bioscience Inc (NAGE) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
